Introduction
============

The purpose of this study was to evaluate the efficacy of telavancin (TLV), a novel bactericidal lipoglycopeptide with a multifunctional mechanism of action, for the treatment of surgical site infections due to Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus*(MRSA).

Methods
=======

The ATLAS program (assessment of TLV in complicated skin and skin structure infections (cSSSI)) consisted of parallel, randomized, double-blind trials including \>1,800 patients with cSSSI who received either TLV 10 mg/kg intravenously every 24 hours or vancomycin (VAN) 1 g intravenously every 12 hours for 7--14 days. This subgroup analysis of ATLAS patients with surgical site cSSSI compared clinical and microbiologic responses to treatment with TLV or VAN.

Results
=======

One hundred and ninety-four patients (10%) had operative-site cSSSI (TLV, *n*= 101; VAN, *n*= 93). Patient characteristics were similar between groups. Among all treated patients, clinical cure was achieved in 78 (77%) TLV patients and 65 (70%) VAN patients. The efficacy of TLV was numerically superior to VAN in SA and MRSA-infected patients (Table [1](#T1){ref-type="table"}) but differences did not reach statistical significance. Incidences of adverse events were generally similar although nausea (28% TLV, 16% VAN), headache (10% TLV, 5% VAN) and taste disturbance (20% TLV, 1% VAN) were more common in the TLV group.

###### 

Clinical cure and pathogen eradication rates by treatment group

                                 TLV SA    VAN SA    TLV MRSA   VAN MRSA
  ------------------------------ --------- --------- ---------- ----------
  Clinical cure, *n*(%)          41 (85)   33 (70)   18 (86)    15 (71)
  Pathogen eradication, *n*(%)   40 (83)   30 (64)   17 (81)    12 (57)

Conclusion
==========

TLV was at least as efficacious as VAN for treatment of operative-site MRSA cSSSI and is a potentially useful treatment option.
